| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | BRD-K02251932 | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.03 | 0.6 |
| mRNA | JQ-1:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | pitstop2 | CTRPv2 | pan-cancer | AAC | -0.026 | 0.6 |
| mRNA | JQ-1 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | EX-527 | GDSC1000 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | 0.028 | 0.6 |
| mRNA | BRD-K29086754 | CTRPv2 | pan-cancer | AAC | -0.036 | 0.6 |